The 2001 World Health Organization (WHO) and the updated European Clinical and Pathological (ECP) criteria for the diagnosis, classification and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders
. Sem Thromb Hemostas 2006;32:307-340.
Prevalence ofJAK2 V619F mutation in Indian patients with chronic myeloproliferative disorders
. Indian J Med Res 2010; 132: 423-27.
However, at least in patients with idiopathic myelofibrosis and other chronic myeloproliferative disorders
, an alternative pathogenesis has been proposed.
Chronic myeloproliferative disorders
(CMPDs) are clonal haematopoietic stem cell disorders and include the BCR-ABL negative CMPDs like polycythemia vera (PV), essential thrombocythemia (ET), idiopathic myelofibrosis (IMF) and chronic eosinophilic leukaemia (CEL) (1,2).
Philadelphia-negative chronic myeloproliferative disorders
(CMDs) are characterized by clonal proliferation of hematopoietic progenitor cells in the bone marrow and by extramedullary hematopoiesis associated with increased [CD34.sup.+] circulating cells (10-12).
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
To establish a diagnosis of ET, reactive causes of thrombocytosis should be absent and other chronic myeloproliferative disorders
should be ruled out (1).
In the absence of pathognomonic markers, the diagnosis of the two chronic myeloproliferative disorders
polycythemia vera (PV) and essential thrombocythemia (ET) has relied on a set of clinical and laboratory criteria (1-5).